“Myriad’s proprietary database would not be very valuable if the public/nonprofit/payor network were sharing data effectively,” said Bob Cook-Deegan. “This ...
Science & Society
Science & Society is an initiative at Duke dedicated to integrating and fostering innovation in research, education, and engagement at the intersection of science and society, especially in the areas of law, policy, genetics, medicine, neuroscience, engineering, and education. Our faculty, post-docs, research associates, and professional staff work together to:
- Improve science communication and the accountability of scientists to the public
- Embed the ethical, legal, and social implications of science in science education
- Use evidence-based research to inform changes in law, government policy, and the behavior of individuals
- Provide a research environment that is more intimately embedded in the community it seeks to support
- Ensure research can deliver tangible, ethical, and beneficial contributions to society
MA in Bioethics & Science Policy
Biotechnology has changed the food we eat, how we communicate, the medicines we use, and so much more. Advances in the sciences and technology shape our lives and our societies, and raise myriad questions: Is it ethical to clone part of a human being? Should we use technologies that enhance or alter our brains? Will we permit the police to store DNA forever, even for those who have never committed a crime? Duke’s MA in Bioethics & Science Policy invites students to address these questions and many more.
Both Science & Society and the MA program are led by Nita Farahany, JD, Ph.D., whose work focuses on the ethical, legal, and social implications of biosciences and emerging technologies, particularly those related to law, neuroscience and behavioral genetics. Since 2010, Professor Farahany has served on President Obama’s Commission for the Study of Bioethical Issues.
The IGSP also houses the Center for Public Genomics (CpG), a Center of Excellence in Ethical, Legal, and Social Implications (ELSI) Research exploring the value of "open science" norms co-funded by the Department of Energy and the NIH.
“With 23andMe, the FDA said you cannot tell people what this genetic information means for their health,” Misha Angrist says. “You can tell them about their ancestry or a gene ...
A US drug-agency clampdown is unwarranted without evidence of harm, say Robert C. Green and Nita A. Farahany.
“It’s the seamy side of happy stories,” says Robert Cook-Deegan. “You have this drug that caused birth defects that’s gone on to help treat cancer. But ...
Would You Terminate a Pregnancy Affected by Sickle Cell Disease? Analysis of Views of Patients in Cameroon
Charmaine Royal and colleagues used a quantitative sociological method, with administered structured questionnaires, to study the attitudes of adult patients suffering from sickle cell ...
Pharmacogenetic Testing in the Face of Unclear Clinical Efficacy: Lessons from Cytochrome P450 2D6 for Tamoxifen
Laura Beskow is a collaborator on a study showing that a minority of oncologists have used the CYP2D6 test routinely.
The U.S. Supreme Court decided that not all gene patents are alike. Bob Cook-Deegan and Arti Rai ask what this means for research, innovation, business, and patients.
Bob Cook-Deegan co-authored a Science Translational Medicine article saying that the blockbuster model of DNA genetic testing has been dealt a substantial blow.